Effect of Semaglutide in Patients With Psoriasis and Obesity

PHASE3RecruitingINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

March 20, 2025

Primary Completion Date

July 31, 2026

Study Completion Date

January 31, 2027

Conditions
Psoriasis (PsO)Obesity and Overweight
Interventions
BIOLOGICAL

semaglutide

Semaglutide is act as an adjunct to a reduced calorie diet and increase physical activity for chronic weight management in adult with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia)

Trial Locations (1)

Unknown

RECRUITING

The University of Hong Kong, Department of Medicine, Hong Kong

All Listed Sponsors
lead

The University of Hong Kong

OTHER